E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Add to balance / Manage account  User:  Log out
Prospect News home > News index > List of issuers G > Headlines for GlaxoSmithKline plc > News item
Published on 5/19/2006 in the Prospect News Biotech Daily.

Flamel Technologies gets $1 million milestone payment

By Elaine Rigoli

Tampa, Fla., May 19 - Flamel Technologies has received a $1 million milestone from its collaborator, GlaxoSmithKline, a payment that was triggered by the successful completion of activities relating to the manufacturing process for Coreg CR microparticles.

Flamel and GlaxoSmithKline completed a supply agreement in December 2004 under which Flamel is responsible for manufacturing Coreg CR microparticles.

Flamel is a drug-discovery company based in Paris.

GlaxoSmithKline is a global pharmaceutical company based in London.


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.